August 21, 2025CureusOpen Access

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Non-diabetic Heart Failure: A Systematic Review of Randomized Controlled Trials and Real-World Evidence

View Full Paper

Ask AI

Bookmark

Authors

MIMohammed O. IbrahimMutah University OMOsama Mahmoud MohamedAbu Dhabi Health Services NANorshamsuri AliUniversiti Malaysia Perlis

Discussion

Member takes

Implication

Systematic review demonstrates reduced hospitalization and mortality in non-diabetic heart failure patients using SGLT2 inhibitors, highlighting significant cardiovascular benefits.

Key Points

SGLT2 inhibitors were linked to lower cardiovascular mortality and reduced hospitalizations in non-diabetic heart failure patients.
Data from six studies, including four randomized controlled trials, involving over 16,000 non-diabetic patients, supported these findings.
Qualitative assessment conducted emphasizes the efficacy of SGLT2 inhibitors in different heart failure phenotypes, such as HFrEF and HFpEF.
Broad implementation of SGLT2 inhibitors in clinical practice could be pivotal for improving outcomes in non-diabetic heart failure populations.

Cite This Study

Ibrahim et al. (2025) studied this question.

synapsesocial.com/papers/68af6d847567bf4f94fea683 https://doi.org/10.7759/cureus.90684

View Full Paper

Ask AI

Bookmark

Implication

Systematic review demonstrates reduced hospitalization and mortality in non-diabetic heart failure patients using SGLT2 inhibitors, highlighting significant cardiovascular benefits.

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Non-diabetic Heart Failure: A Systematic Review of Randomized Controlled Trials and Real-World Evidence

Discussion

Member takes

Implication

Key Points

Cite This Study

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Non-diabetic Heart Failure: A Systematic Review of Randomized Controlled Trials and Real-World Evidence

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider